Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

BioRestorative Therapies, Inc.

CIK 1505497 BRTX·Services · All EDGAR filings ↗

Progression

  1. Finance chief departure 8-K
  2. Late filing NT 10-Q +29d
  3. Auditor change 8-K +19d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Auditor change high SEC item code

BioRestorative Therapies, Inc. moved from CBIZ to Bush & Associates CPA

The company dismissed the auditor. CBIZ → Bush & Associates CPA LLC to a smaller firm No disagreements disclosed.

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Disagreements disclosed
No
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
CBIZ
Predecessor tier
national
Severity
high
Source
SEC 8-K item code
Successor auditor
Bush & Associates CPA LLC
Successor tier
other
Tier downgrade
Yes
Why
The company's independent registered accounting firm changed.
Successor auditor as filed
Bush & Associates CPA

Source filing ↗

Auditor change high SEC item code

CBIZ resigned as BioRestorative Therapies, Inc.'s auditor

The auditor resigned. CBIZ → Bush & Associates CPA LLC to a smaller firm

Evidence
Direction
resigned
Direction label
The auditor resigned
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
CBIZ
Predecessor tier
national
Severity
high
Source
SEC 8-K item code
Successor auditor
Bush & Associates CPA LLC
Successor tier
other
Tier downgrade
Yes
Why
The company's independent registered accounting firm changed.
Successor auditor as filed
Bush & Associates CPA

Source filing ↗

Finance chief departure elevated Filing comparison

BioRestorative Therapies, Inc.'s Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Late filing high Filing comparison

BioRestorative Therapies, Inc. filed its quarterly report late and said it expects a significant change in results

expects significant change in results Filed on the statutory due date.

As previously reported, in July 2026 the Company’s President, Chief Executive Officer and Chairman of the Board and the Company’s Chief Financial Officer each resigned. Each officer asserted that his resignation was for “good reason” under an employment agreement purportedly entered into between the Company and such officer. The Company disputes the validity and enforceability of the purported employment agreements and the asserted basis for the resignations, and has reserved all of its rights with respect thereto. The office of Chief Financial Officer is held on an interim basis by the Company’s Chief Executive Officer, and the resulting reduction in the Company’s financial reporting…
Evidence
Anticipates significant change
Yes
Days past due date
0
Routine
No
Severity
high
Source
Form 12b-25 (notification of late filing)
Stated reason
As previously reported, in July 2026 the Company’s President, Chief Executive Officer and Chairman of the Board and the Company’s Chief Financial Officer each resigned. Each officer asserted that his resignation was for “good reason” under an employment agreement purportedly entered into between the Company and such officer. The Company disputes the validity and enforceability of the purported employment agreements and the asserted basis for the resignations, and has reserved all of its rights with respect thereto. The office of Chief Financial Officer is held on an interim basis by the Company’s Chief Executive Officer, and the resulting reduction in the Company’s financial reporting…
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Finance chief departure elevated Filing comparison

BioRestorative Therapies, Inc.'s Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗